Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843762 · ClinicalTrials.gov registry record
Harnessing Sleep/Circadian Rhythm Data as a Biomarker to Mitigate Health Risks
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 106
- Enrollment target
NCT03843762: Completed study, sponsored by Duke University.
NCT03843762 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03843762 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 106 participants
- Enrollment target
Study Summary
The overall goal of this study is to investigate associations between sleep/circadian disturbances and psychiatric health among adolescents recruited from primary and specialty health clinics.
Primary Outcome
"Internalizing symptoms" and "Externalizing symptoms" subscales of the Child Behavior Checklist (CBCL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2020-03-16 |
What the finished NCT03843762 record still lists
NCT03843762 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03843762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03843762 about?
NCT03843762 is a clinical study titled "Harnessing Sleep/Circadian Rhythm Data as a Biomarker to Mitigate Health Risks". The overall goal of this study is to investigate associations between sleep/circadian disturbances and psychiatric health among adolescents recruited from primary and specialty health clinics.
What is the current status of trial NCT03843762?
This trial is currently completed. The enrollment target is 106 participants. The study started on 2019-05-06. Estimated completion is 2020-03-16.
Who is sponsoring clinical trial NCT03843762?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI